As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $51
Hold Rating on Bristol-Myers Squibb Amid Patent Expirations and Speculative Prospects of Milvexian
Express News | Bristol-Myers Squibb Co : Jefferies Raises Target Price to $51 From $49
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Market Whales and Their Recent Bets on BMY Options
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
Merck, Bristol Myers Cancer Drugs Included in September FDA Advisory Panel Meeting
Bristol-Myers Squibb Company's (NYSE:BMY) Latest 3.0% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Express News | Bristol-Myers Squibb Says FDA Schedules Oncologic Drugs Advisory Committee Meeting For September 26 To Discuss PD-L1 Expression Levels In Gastric And Esophageal Cancers
Express News | Bristol-Myers Squibb Co - Meeting to Discuss Pd-L1 Expression Levels in Gastric and Esophageal Cancers
Express News | Bristol-Myers Squibb Co - FDA Will Hold a Public Meeting of the Oncologic Drugs Advisory Committee (Odac) on September 26
Express News | Zenas Biopharma Inc Says Bristol-Myers Squibb Co, Xencor Inc Are Among 5% or Greater Stockholders in the Company
Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review
Bristol-Myers Squibb Is Maintained at Underweight by Barclays
Bristol-Myers Squibb Analyst Ratings
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Announces Target Price $42